Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors

被引：2
|
作者：
Janku, Filip [1 ]
Birrer, Michael [2 ]
Richardson, Debra [3 ]
Chu, Christina [4 ]
Goel, Sanjay [5 ]
Su, Ying [6 ]
Matin, Bahar [6 ]
Kuida, Keisuke [6 ]
Ruiz-Soto, Rodrigo [6 ]
Hamilton, Erika Paige [7 ,8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA
[4] Fox Chase Canc Ctr, Havertown, PA USA
[5] Albert Einstein Coll Med, Bronx, NY 10467 USA
[6] Deciphera Pharmaceut LLC, Waltham, MA USA
[7] Sarah Cannon Res Inst, Nashville, TN USA
[8] Tennessee Oncol PLLC, Nashville, TN USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Azzoli, Christopher G.
    Krug, Lee M.
    Gomez, Jorge
    Miller, Vincent A.
    Kris, Mark G.
    Ginsberg, Michelle S.
    Henry, Roxanne
    Jones, Jessica
    Tyson, Leslie
    Dunne, Megan
    Pizzo, Barbara
    Farmer, Amy
    Venkatraman, Ennapadam
    Steffen, Robert
    Sirotnak, F. M.
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2692 - 2698
  • [32] A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Jonker, D. J.
    Rosen, L. S.
    Sawyer, M. B.
    de Braud, F.
    Wilding, G.
    Sweeney, C. J.
    Jayson, G. C.
    McArthur, G. A.
    Rustin, G.
    Goss, G.
    Kantor, J.
    Velasquez, L.
    Syed, S.
    Mokliatchouk, O.
    Feltquate, D. M.
    Kollia, G.
    Nuyten, D. S. A.
    Galbraith, S.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1413 - 1419
  • [33] Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 Study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Oishi, Masayo
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
  • [35] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors
    Sharma, Neelesh
    Wesolowski, Robert
    Reebel, Laura
    Rodal, Mary Beth
    Peck, Alexandra
    West, Brian
    Karlin, David Alan
    Dowlati, Afshln
    Le, Mal H.
    Coussens, Lisa M.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.
    Naing, Aung
    Fan, Jean
    Lee, Byung Ha
    Basudhar, Debashree
    Pant, Shubham
    Chaney, Marya F.
    Laviada, Cristina
    Rajan, Cynthia
    Le, Ngocdiep T.
    Barve, Minal A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
    Shemesh, Colby S.
    Wang, Yongsheng
    An, Andrew
    Ding, Hao
    Chan, Phyllis
    Liu, Qi
    Chen, Yih-Wen
    Wu, Benjamin
    Wu, Qiong
    Wang, Xian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 45 - 55
  • [39] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
    Geva, Ravit
    Stemmer, Salomon
    Perets, Ruth
    Maurice-Dror, Corinne
    Ben-Ami, Eitan
    Raphael, Ari
    Kumar, Sanjeev
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Fields, Scott Z.
    Rozencweig, Marcel
    Golan, Talia
    CANCER RESEARCH, 2023, 83 (08)
  • [40] Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
    Paluri, Ravi Kumar
    Li, Peng
    Jones, Benjamin Scott
    Madan, Ankit
    Jerome, Mary
    Miley, Debi
    Keef, Jennifer
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345